Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells

Takashi Mine, Satoko Matsueda, Yufeng Li, Hiroshi Tokumitsu, Hui Gao, Cristopher Danes, Kwong Kwok Wong, Xinhui Wang, Soldano Ferrone, Constantin G. Ioannides

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-fluorouracil (5-FU) and (2) their elimination by Numb- and Notch-peptide activated CTL. The number of cells in all populations with the luminal CSC phenotype [epithelial specific antigen+ (ESA) CD44hi CD24lo, CD44hi CD133+, and CD133+ CD24lo] increased in drug-resistant MCF7 and SK-OV-3 cells. Similarly, the number of cells with expressed MIC-A/B increased 4 times in drug-resistant tumor cells compared with drug-sensitive cells. GEMRes MCF7 cells had lower levels of the Notch-1-extracellular domain (NECD) and Notch trans-membrane intracellular domain (TMIC) than GEMSens MCF7. The levels of Numb, and Numb-L-[P]-Ser265 were similar in GEM Res and GEMSens MCF7 cells. Only the levels of Numb-L (long)-Ser295 decreased slightly. This finding suggests that Notch-1 cleavage to TMIC is inhibited in GEMRes MCF7 cells. PBMC activated by natural immunogenic peptides Notch-1 (2112-2120) and Numb-1 (87-95) eliminated NICDpositive, CD24hi CD24lo MCF7 cells. It is likely that the immunogenic Numb-1 peptide in MCF7 cells originated from Numb, [P]-lated by an unknown kinase, because staurosporine but not wortmannin and MAPK-inhibitors decreased peptide presentation. Numb and Notch are antagonistic proteins which degrade each other to stop and activate cell proliferation, respectively. Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments.

Original languageEnglish
Pages (from-to)1185-1194
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume58
Issue number8
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

Fingerprint

Peptide T
MCF-7 Cells
gemcitabine
Stem Cells
Neoplastic Stem Cells
Breast Neoplasms
T-Lymphocytes
Peptides
Intracellular Membranes
Cell Count
Pharmaceutical Preparations
Notch Receptors
Staurosporine
Paclitaxel
Fluorouracil
Neoplasms
Breast
Phosphotransferases
Radiotherapy
Cell Proliferation

Keywords

  • Breast/ovarian
  • Cancer stem cell
  • Drug resistance
  • Notch
  • Numb
  • Peptide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. / Mine, Takashi; Matsueda, Satoko; Li, Yufeng; Tokumitsu, Hiroshi; Gao, Hui; Danes, Cristopher; Wong, Kwong Kwok; Wang, Xinhui; Ferrone, Soldano; Ioannides, Constantin G.

In: Cancer Immunology, Immunotherapy, Vol. 58, No. 8, 08.2009, p. 1185-1194.

Research output: Contribution to journalArticle

Mine, T, Matsueda, S, Li, Y, Tokumitsu, H, Gao, H, Danes, C, Wong, KK, Wang, X, Ferrone, S & Ioannides, CG 2009, 'Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells', Cancer Immunology, Immunotherapy, vol. 58, no. 8, pp. 1185-1194. https://doi.org/10.1007/s00262-008-0623-1
Mine, Takashi ; Matsueda, Satoko ; Li, Yufeng ; Tokumitsu, Hiroshi ; Gao, Hui ; Danes, Cristopher ; Wong, Kwong Kwok ; Wang, Xinhui ; Ferrone, Soldano ; Ioannides, Constantin G. / Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. In: Cancer Immunology, Immunotherapy. 2009 ; Vol. 58, No. 8. pp. 1185-1194.
@article{397f3d4fabde43c08677e0b3008df28e,
title = "Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells",
abstract = "Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-fluorouracil (5-FU) and (2) their elimination by Numb- and Notch-peptide activated CTL. The number of cells in all populations with the luminal CSC phenotype [epithelial specific antigen+ (ESA) CD44hi CD24lo, CD44hi CD133+, and CD133+ CD24lo] increased in drug-resistant MCF7 and SK-OV-3 cells. Similarly, the number of cells with expressed MIC-A/B increased 4 times in drug-resistant tumor cells compared with drug-sensitive cells. GEMRes MCF7 cells had lower levels of the Notch-1-extracellular domain (NECD) and Notch trans-membrane intracellular domain (TMIC) than GEMSens MCF7. The levels of Numb, and Numb-L-[P]-Ser265 were similar in GEM Res and GEMSens MCF7 cells. Only the levels of Numb-L (long)-Ser295 decreased slightly. This finding suggests that Notch-1 cleavage to TMIC is inhibited in GEMRes MCF7 cells. PBMC activated by natural immunogenic peptides Notch-1 (2112-2120) and Numb-1 (87-95) eliminated NICDpositive, CD24hi CD24lo MCF7 cells. It is likely that the immunogenic Numb-1 peptide in MCF7 cells originated from Numb, [P]-lated by an unknown kinase, because staurosporine but not wortmannin and MAPK-inhibitors decreased peptide presentation. Numb and Notch are antagonistic proteins which degrade each other to stop and activate cell proliferation, respectively. Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments.",
keywords = "Breast/ovarian, Cancer stem cell, Drug resistance, Notch, Numb, Peptide",
author = "Takashi Mine and Satoko Matsueda and Yufeng Li and Hiroshi Tokumitsu and Hui Gao and Cristopher Danes and Wong, {Kwong Kwok} and Xinhui Wang and Soldano Ferrone and Ioannides, {Constantin G.}",
year = "2009",
month = "8",
doi = "10.1007/s00262-008-0623-1",
language = "English",
volume = "58",
pages = "1185--1194",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells

AU - Mine, Takashi

AU - Matsueda, Satoko

AU - Li, Yufeng

AU - Tokumitsu, Hiroshi

AU - Gao, Hui

AU - Danes, Cristopher

AU - Wong, Kwong Kwok

AU - Wang, Xinhui

AU - Ferrone, Soldano

AU - Ioannides, Constantin G.

PY - 2009/8

Y1 - 2009/8

N2 - Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-fluorouracil (5-FU) and (2) their elimination by Numb- and Notch-peptide activated CTL. The number of cells in all populations with the luminal CSC phenotype [epithelial specific antigen+ (ESA) CD44hi CD24lo, CD44hi CD133+, and CD133+ CD24lo] increased in drug-resistant MCF7 and SK-OV-3 cells. Similarly, the number of cells with expressed MIC-A/B increased 4 times in drug-resistant tumor cells compared with drug-sensitive cells. GEMRes MCF7 cells had lower levels of the Notch-1-extracellular domain (NECD) and Notch trans-membrane intracellular domain (TMIC) than GEMSens MCF7. The levels of Numb, and Numb-L-[P]-Ser265 were similar in GEM Res and GEMSens MCF7 cells. Only the levels of Numb-L (long)-Ser295 decreased slightly. This finding suggests that Notch-1 cleavage to TMIC is inhibited in GEMRes MCF7 cells. PBMC activated by natural immunogenic peptides Notch-1 (2112-2120) and Numb-1 (87-95) eliminated NICDpositive, CD24hi CD24lo MCF7 cells. It is likely that the immunogenic Numb-1 peptide in MCF7 cells originated from Numb, [P]-lated by an unknown kinase, because staurosporine but not wortmannin and MAPK-inhibitors decreased peptide presentation. Numb and Notch are antagonistic proteins which degrade each other to stop and activate cell proliferation, respectively. Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments.

AB - Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-fluorouracil (5-FU) and (2) their elimination by Numb- and Notch-peptide activated CTL. The number of cells in all populations with the luminal CSC phenotype [epithelial specific antigen+ (ESA) CD44hi CD24lo, CD44hi CD133+, and CD133+ CD24lo] increased in drug-resistant MCF7 and SK-OV-3 cells. Similarly, the number of cells with expressed MIC-A/B increased 4 times in drug-resistant tumor cells compared with drug-sensitive cells. GEMRes MCF7 cells had lower levels of the Notch-1-extracellular domain (NECD) and Notch trans-membrane intracellular domain (TMIC) than GEMSens MCF7. The levels of Numb, and Numb-L-[P]-Ser265 were similar in GEM Res and GEMSens MCF7 cells. Only the levels of Numb-L (long)-Ser295 decreased slightly. This finding suggests that Notch-1 cleavage to TMIC is inhibited in GEMRes MCF7 cells. PBMC activated by natural immunogenic peptides Notch-1 (2112-2120) and Numb-1 (87-95) eliminated NICDpositive, CD24hi CD24lo MCF7 cells. It is likely that the immunogenic Numb-1 peptide in MCF7 cells originated from Numb, [P]-lated by an unknown kinase, because staurosporine but not wortmannin and MAPK-inhibitors decreased peptide presentation. Numb and Notch are antagonistic proteins which degrade each other to stop and activate cell proliferation, respectively. Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments.

KW - Breast/ovarian

KW - Cancer stem cell

KW - Drug resistance

KW - Notch

KW - Numb

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=67349164276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349164276&partnerID=8YFLogxK

U2 - 10.1007/s00262-008-0623-1

DO - 10.1007/s00262-008-0623-1

M3 - Article

VL - 58

SP - 1185

EP - 1194

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -